AR antagonists, such as enzalutamide or seviteronel, exhibited a synergistic effect when co-administered with anti-HER2 drugs, like everolimus and trastuzumab, in BC cells resistant to anti-HER2 therapy [231]. The gene discussed is ERBB2; the disease is breast cancer.